
Product Data Sheet

Brilliant Violet 570[™] anti-mouse CD8a

Catalog # / Size:	1103700 / 50 μg 1103695 / 125 μl
Clone:	53-6.7
Isotype:	Rat IgG2a, к
Immunogen:	Mouse thymus or spleen
Reactivity:	Mouse
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 570 [™] under optimal conditions. The solution is free of unconjugated Brilliant Violet 570 [™] and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Concentration:	microg sizes: 0.2 mg/ml microL sizes: lot-specific




C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8a (clone 53-6.7) Brilliant Violet 570[™] (top) or rat IgG2a, κ Brilliant Violet 570[™] isotype control (bottom).

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the microg size, the suggested use of this reagent is ≤ 0.5 microg per million cells in 100 microL volume. For immunofluorescent staining using the microL size, the suggested use of this reagent is ≤ 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
	Brilliant Violet 570 [™] excites at 405 nm and emits at 570 nm. The bandpass filter 585/42 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or

manufacturer for support. Brilliant Violet 570[™] is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The



purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Clone 53-6.7 antibody competes with Notes: clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a⁺ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation^{1,3}, in vivo and *in vitro* cell depletion^{2,10,15}, inhibition of CD8 T cell proliferation3, cytotoxicity^{3,4}, blocking and of immunohistochemical staining^{5,6} of acetone-fixed frozen sections and zincfixed paraffin-embedded sections. Clone 53-6.7 not recommended is for immunohistochemistry of formalin-fixed paraffin sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100716). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF purified antibody (Cat. No. 100746) with a lower endotoxin limit than standard LEAF[™] purified antibodies (Endotoxin <0.01 EU/microg). Application 1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) 2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) **References:** 3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) 4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) 5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) 6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) 7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) 8. Kamimura D, et al. 2006. J. Immunol. 177:306. 9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) 10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed 11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed 12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed 13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed 14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed 15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed 16. Guo Y, et al. 2008. Blood 112:480. PubMed 17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed 18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed 19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed 20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed 21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed 22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed 23. Medyouf H, et al. 2010. Blood 115:1175. PubMed 24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed 25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed

26. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) <u>PubMed</u>

27. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) <u>PubMed</u>

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com **Description:** CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α (CD8a)/ β (CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigenpresenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. Antigen 2. Zamoyska R. 1994. Immunity 1:243.

- **References:**
 - 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.